About this trial
The purpose of this study is to investigate if Cemiplimab is better than placebo when a CSCC patient has been treated after they have had both surgery and radiotherapy. This is a Phase 3 trial. It is planned that the study’s primary completion date will be 16 OCT 2023, follow-up activities will continue until 11 FEB 2026.
Patient Profile
Adults aged 18 years and older, ECOG Performance status score ≤1
Where’s this trial being run?
Cork University Hospital, St Vincents University Hospital, and University Hospital Galway
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | R2810-ONC-1788 |
|---|---|
| Number: | 18-50 |
| Full Title: | A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma |
| Principal Investigator: | Dr Derek Power |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Regeneron Pharmaceuticals |
| Recruitment Started: |
Global: 31 JUL 2019 Ireland: 24 JAN 2020 |
| Global Recruitment Target: | 412 |
|---|---|
| Ireland Recruitment Target: | 8 |